These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 16335681

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome.
    Menke LA, Sas TC, de Muinck Keizer-Schrama SM, Zandwijken GR, de Ridder MA, Odink RJ, Jansen M, Delemarre-van de Waal HA, Stokvis-Brantsma WH, Waelkens JJ, Westerlaken C, Reeser HM, van Trotsenburg AS, Gevers EF, van Buuren S, Dejonckere PH, Hokken-Koelega AC, Otten BJ, Wit JM.
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1151-60. PubMed ID: 20061421
    [Abstract] [Full Text] [Related]

  • 3. Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age.
    Stahnke N, Keller E, Landy H, Serono Study Group.
    J Pediatr Endocrinol Metab; 2002 Feb; 15(2):129-38. PubMed ID: 11874177
    [Abstract] [Full Text] [Related]

  • 4. Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome.
    Zeger MP, Shah K, Kowal K, Cutler GB, Kushner H, Ross JL.
    Horm Res Paediatr; 2011 Feb; 75(1):38-46. PubMed ID: 20733274
    [Abstract] [Full Text] [Related]

  • 5. [The effect of primary lack of estrogens and the influence of the age at the beginning of estrogen therapy on bone mineral density in patients with Turner's syndrome].
    Sowińska-Przepiera E, Andrysiak-Mamos E, Friebe Z, Kapczuk K, Pilarska K.
    Endokrynol Pol; 2005 Feb; 56(2):145-53. PubMed ID: 16335682
    [Abstract] [Full Text] [Related]

  • 6. The effect of the weak androgen oxandrolone on psychological and behavioral characteristics in growth hormone-treated girls with Turner syndrome.
    Menke LA, Sas TC, Visser M, Kreukels BP, Stijnen T, Zandwijken GR, de Muinck Keizer-Schrama SM, Otten BJ, Wit JM, Cohen-Kettenis PT.
    Horm Behav; 2010 Mar; 57(3):297-305. PubMed ID: 20053349
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Delemarre-van de Waal HA, Vulsma T, Wit JM, Rouwé CW, Reeser HM, Gosen JJ, Rongen-Westerlaken C, Drop SL.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4013-21. PubMed ID: 8923853
    [Abstract] [Full Text] [Related]

  • 9. The effect of oxandrolone on voice frequency in growth hormone-treated girls with Turner syndrome.
    Menke LA, Sas TC, van Koningsbrugge SH, de Ridder MA, Zandwijken GR, Boersma B, Dejonckere PH, de Muinck Keizer-Schrama SM, Otten BJ, Wit JM.
    J Voice; 2011 Sep; 25(5):602-10. PubMed ID: 20971614
    [Abstract] [Full Text] [Related]

  • 10. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone.
    Nilsson KO, Albertsson-Wikland K, Alm J, Aronson S, Gustafsson J, Hagenäs L, Häger A, Ivarsson SA, Karlberg J, Kriström B, Marcus C, Moell C, Ritzen M, Tuvemo T, Wattsgård C, Westgren U, Westphal O, Aman J.
    J Clin Endocrinol Metab; 1996 Feb; 81(2):635-40. PubMed ID: 8636281
    [Abstract] [Full Text] [Related]

  • 11. Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database).
    Darendeliler F, Ranke MB, Bakker B, Lindberg A, Cowell CT, Albertsson-Wikland K, Reiter EO, Price DA.
    Horm Res; 2005 Feb; 63(1):40-7. PubMed ID: 15627781
    [Abstract] [Full Text] [Related]

  • 12. GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial.
    Arends NJ, Boonstra VH, Mulder PG, Odink RJ, Stokvis-Brantsma WH, Rongen-Westerlaken C, Mulder JC, Delemarre-Van de Waal H, Reeser HM, Jansen M, Waelkens JJ, Hokken-Koelega AC.
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):779-87. PubMed ID: 14974922
    [Abstract] [Full Text] [Related]

  • 13. Effect of oxandrolone and timing of oral ethinylestradiol initiation on pubertal progression, height velocity and bone maturation in the UK Turner study.
    Perry RJ, Gault EJ, Paterson WF, Dunger DB, Donaldson MD.
    Horm Res Paediatr; 2014 Dec; 81(5):298-308. PubMed ID: 24751470
    [Abstract] [Full Text] [Related]

  • 14. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial.
    Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Massa GG, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL.
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4607-12. PubMed ID: 10599727
    [Abstract] [Full Text] [Related]

  • 15. Growth-promoting effect of growth hormone and low dose ethinyl estradiol in girls with Turner's syndrome.
    Vanderschueren-Lodeweyckx M, Massa G, Maes M, Craen M, van Vliet G, Heinrichs C, Malvaux P.
    J Clin Endocrinol Metab; 1990 Jan; 70(1):122-6. PubMed ID: 2294126
    [Abstract] [Full Text] [Related]

  • 16. Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome.
    Freriks K, Sas TC, Traas MA, Netea-Maier RT, den Heijer M, Hermus AR, Wit JM, van Alfen-van der Velden JA, Otten BJ, de Muinck Keizer-Schrama SM, Gotthardt M, Dejonckere PH, Zandwijken GR, Menke LA, Timmers HJ.
    Eur J Endocrinol; 2013 Jan; 168(1):91-9. PubMed ID: 23076845
    [Abstract] [Full Text] [Related]

  • 17. Oxandrolone for growth hormone-treated girls aged up to 18 years with Turner syndrome.
    Mohamed S, Alkofide H, Adi YA, Amer YS, AlFaleh K.
    Cochrane Database Syst Rev; 2019 Oct 30; 2019(10):. PubMed ID: 31684688
    [Abstract] [Full Text] [Related]

  • 18. Gradually increasing ethinyl estradiol for Turner syndrome may produce good final height but not ideal BMD.
    Hasegawa Y, Ariyasu D, Izawa M, Igaki-Miyamoto J, Fukuma M, Hatano M, Yagi H, Goto M.
    Endocr J; 2017 Feb 27; 64(2):221-227. PubMed ID: 27916781
    [Abstract] [Full Text] [Related]

  • 19. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height.
    Quigley CA, Crowe BJ, Anglin DG, Chipman JJ.
    J Clin Endocrinol Metab; 2002 May 27; 87(5):2033-41. PubMed ID: 11994337
    [Abstract] [Full Text] [Related]

  • 20. A longitudinal study on bone mineral density until adulthood in girls with Turner's syndrome participating in a growth hormone injection frequency-response trial.
    Sass TC, De Muinck Keizer-Schrama SM, Stijnen T, Asarfi A, Van Leeuwen WJ, Van Teunenbroek A, Van Rijn RR, Drop SL.
    Clin Endocrinol (Oxf); 2000 May 27; 52(5):531-6. PubMed ID: 10792330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.